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The central site(s) mediating the cardiovascular actions of the apelin-apelin receptor
(APJ) system remains a major question. We hypothesized that the sensory
circumventricular organs (CVOs), interfacing between the circulation and deeper brain
structures, are sites where circulating apelin acts as a signal in the central nervous
system to decrease blood pressure (BP). We show that APJ gene (aplnr) expression
was elevated in the CVOs of spontaneously hypertensive rats (SHRs) compared
to normotensive Wistar Kyoto (WKY) controls, and that there was a greater mean
arterial BP (MABP) decrease following microinjection of [Pyr1]apelin-13 to the CVOs
of SHRs compared to WKY rats. Lentiviral APJ-specific-shRNA (LV-APJ-shRNA) was
used to knockdown aplnr expression, both collectively in three CVOs and discretely in
individual CVOs, of rats implanted with radiotelemeters to measure arterial pressure. LV-
APJ-shRNA-injection decreased aplnr expression in the CVOs and abolished MABP
responses to microinjection of [Pyr1]apelin-13. Chronic knockdown of aplnr in any
of the CVOs, collectively or individually, did not affect basal MABP in SHR or WKY
rats. Moreover, knockdown of aplnr in any of the CVOs individually did not affect
the depressor response to systemic [Pyr1]apelin-13. By contrast, multiple knockdown
of aplnr in the three CVOs reduced acute cardiovascular responses to peripheral
[Pyr1]apelin-13 administration in SHR but not WKY rats. These results suggest that
endogenous APJ activity in the CVOs has no effect on basal BP but that functional APJ
in the CVOs is required for an intact cardiovascular response to peripherally administered
apelin in the SHR.
Keywords: apelin, apelin receptor (APJ), circumventricular organs (CVOs), hypertension, spontaneously
hypertensive rat (SHR)
INTRODUCTION
Dysfunctions in mechanisms that regulate blood pressure (BP) participate in the development
of hypertension that is mediated, in part, by activation of the sympathetic nervous system (SNS)
(Zubcevic et al., 2011; Fisher and Paton, 2012) or by renal control of peripheral vascular resistance
and body fluid volume (Wadei and Textor, 2012). A significant percentage of patients with essential
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hypertension, that accounts for 95% of all cases of hypertension
(Carretero and Oparil, 2000), exhibit chronic sympathetic
hyperactivity, but the causative mechanisms remain unclear.
The neuropeptide apelin (gene name apln) has well-
established effects on cardiovascular and BP regulation via central
and peripheral targets (O’Carroll et al., 2013) and mediates
its effects via activation of the apelin receptor APJ (O’Dowd
et al., 1993) (gene name aplnr). Apln encodes a 77-amino acid
precursor (Tatemoto et al., 1998) that is enzymatically cleaved
into several bioactive fragments, e.g., apelin-36, apelin-13, and
subsequently processed into [Pyr1]apelin-13, which is the most
abundant apelin isoform in the cardiovascular system (Maguire
et al., 2009). APJ has highest homology to the angiotensin II
receptor type AT1 and has been shown to antagonize the pressor
effects of angiotensin II (Ang II) (Ishida et al., 2004; Siddiquee
et al., 2013) by up-regulation of angiotensin-converting enzyme
2 (ACE2) and suppression of Ang II signaling (Sato et al., 2019).
APJ and apelin are known key regulators of responses to multiple
homeostatic perturbations including cardiovascular (Lee et al.,
2000; Reaux et al., 2001; Seyedabadi et al., 2002; Ishida et al.,
2004; Kuba et al., 2007; Kang et al., 2013; Wang et al., 2015;
Yang et al., 2017), fluid (O’Carroll and Lolait, 2003), and food
intake regulation (Reaux-Le Goazigo et al., 2011). The apelinergic
system is implicated in cardiovascular and metabolic disease
etiology and may act to mitigate the pathogenesis of heart failure
and hypertension (Barnes et al., 2010) and of obesity-induced
disorders that are common predisposing factors in hypertension
(Dray et al., 2008; Sawane et al., 2013; O’Harte et al., 2018;
Parthsarathy et al., 2018). Apelin and APJ mRNA and protein
are expressed in the central nervous system (CNS), in regions
such as the hypothalamic paraventricular nucleus (PVN) and
the rostral ventrolateral medulla (RVLM) that participate in
the control of BP, and also in a variety of peripheral organs
including the pituitary gland, heart, adipose tissue, kidney, and
gastrointestinal tract (O’Carroll et al., 2013). Aplnr expression
in the PVN is up-regulated in response to acute and repeated
stress (O’Carroll et al., 2003), while expression of apln is up-
regulated in cardiac myocytes by hypoxia (Ronkainen et al.,
2007). Insulin elevates both aplnr and apln expression, and
apelin production, in adipose tissue (Sörhede Winzell et al.,
2005; Dray et al., 2010). Furthermore, plasma apelin levels are
increased by glucose administration (Soriguer et al., 2009) and
in certain conditions such as heart failure with chronic systemic
hypoxia (Ferdinal et al., 2019), and decreased by osmotic stimuli
(De Mota et al., 2004). Plasma apelin concentration is also
increased in insulin resistant subjects (Li et al., 2006), in type
2 diabetic (T2D) patients (Cavallo et al., 2012), and in obese
individuals (Boucher et al., 2005). The peripheral apelinergic
system appears to be down-regulated in hypertensive disease,
with changes in the levels of both immunoreactive (ir)-APJ
and/or apln/apelin in human (Sonmez et al., 2010; Chandra et al.,
2011; Zhu et al., 2013) and some rodent hypertension models
(Zhang et al., 2006).
The cardiovascular effects of apelin differ depending on
whether it is administered centrally or peripherally. Apelin
activates pressor mechanisms in the brain, where direct
injection into the PVN or RVLM of rats increases BP
(Seyedabadi et al., 2002; Zhang et al., 2009, 2014; Griffiths et al.,
2018), while the overall effect of peripherally administered apelin,
which may be acting via APJ present at peripheral and/or central
sites, decreases BP in multiple animal models (Lee et al., 2000;
Reaux et al., 2001; Mitra et al., 2006; Siddiquee et al., 2013),
with the magnitude of the depressor effect being enhanced in
hypertensive animals such as the spontaneously hypertensive
rat (SHR) (Lee et al., 2005). Interestingly, APJ and apelin
mRNAs are expressed within the sensory circumventricular
organs (CVOs) (Hatzelmann et al., 2009; Griffiths et al., 2020),
comprised of the subfornical organ (SFO), organum vasculosum
of lamina terminalis (OVLT), and the area postrema (AP).
These anatomical sites, lacking a blood-brain barrier (BBB),
have an important role in cardiovascular regulation (Cottrell
and Ferguson, 2004); they act as anatomical conduits to
major sympathetic regulatory centers (McKinley et al., 2001)
and display a variety of efferent and afferent inter-neuronal
connections that may contribute to a composite cardiovascular
response (Swanson and Kuypers, 1980; Hasser et al., 2000;
Cottrell and Ferguson, 2004). CVO neurons acts as sensors
for circulating neuropeptides such as Ang II (Sunn et al.,
2003), leptin (Smith et al., 2009), and vasopressin (Smith
and Ferguson, 1997), indicating an established role for these
organs as sites for monitoring peripheral signals. Microinjection
of apelin into the SFO decreases BP (Dai et al., 2013), a
cardiovascular response similar to that seen with peripheral
administration of apelin. Additionally, we have shown increased
aplnr expression in the SFO of SHRs [an established and well-
characterized model of hypertension (Trippodo and Frohlich,
1981)] in comparison to control Wistar Kyoto (WKY) rats
(Griffiths et al., 2020), providing evidence of a likely association
for SFO APJ in the pathogenesis of hypertension in the SHR.
The role of the apelinergic system in CVO functions other
than electrophysiological and cardiovascular responses, such as
sodium and water balance, is not known.
While the sites by which circulating apelin exerts its
central effects to modulate BP are undetermined, the sensory
CVOs, in addition to the PVN and RVLM, may mediate
the cardiovascular actions of apelin. We hypothesized that
the sensory CVOs act as a link integrating the effects of
circulating and central apelin on BP regulation. In this
study we used RNA interference (RNAi) to examine whether
down-regulation of aplnr expression in individual sensory
CVOs, or alternatively simultaneous down-regulation of aplnr
expression in three sensory CVOs in the same animal, blocks
the effects of central and/or peripheral circulating apelin




All experiments were approved by the University of Bristol
Animal Welfare and Ethical Review Body and performed in
strict accordance with U.K. Home Office regulations [Animals
(Scientific Procedures) Act (1986)].
Frontiers in Physiology | www.frontiersin.org 2 August 2021 | Volume 12 | Article 711041
fphys-12-711041 July 29, 2021 Time: 16:27 # 3
Griffiths et al. Aplnr Knockdown in Sensory CVOs
Animals
Adult male (∼250 g) Wistar (n = 18, Charles River,
United Kingdom), Wistar Kyoto (WKY; n = 34; Envigo,
United Kingdom) and adult spontaneously hypertensive rats
(SHR; n = 34; Envigo, United Kingdom) were housed at a
constant temperature (21 ± 2◦C) and humidity on a 14:10 h
light:dark cycle. Access to standard laboratory chow and water
was provided ad libitum.
Acute Exogenous [Pyr1]apelin-13
Microinjection Into CVOs
To establish CVO co-ordinates and for preliminary investigation
of [Pyr1]apelin-13 pharmacology in each CVO, Wistar rats were
anesthetized by intraperitoneal (i.p.) injection of sodium
pentobarbital (50 mg/kg). All surgical procedures were
performed under aseptic conditions under a surgical plane
of anesthesia as indicated by the absence of withdrawal reflex to
hindpaw pinch, which was monitored throughout the procedure
and additional doses of anesthetic given as necessary. BP
was monitored via a heparin-saline (1 U/ml) filled catheter
(Micro-Renathane tubing, 0.8 mm inner diameter, Braintree
Scientific) implanted in the left or right femoral artery and
connected to a pressure transducer (BD DTX Plus, Southwest
Medical, Bristol, United Kingdom). For injections to the SFO
and OVLT the head was secured in a stereotaxic frame with the
head held level (confirmed by bregma and lambda having the
same depth coordinate). For injections to the AP the head was
flexed down (nose bar at −19 mm), and the atlanto-occipital
membrane pierced to allow visualization, with the aid of a
binocular surgical microscope (Leica M651, United Kingdom),
of the AP as a highly vascularized structure above the Obex
on the midline dorsal surface of the medulla oblongata. The
CVOs were targeted using previously established stereotaxic
co-ordinates: OVLT: 0.4 mm rostral to bregma, 0 mm lateral to
midline, 8.0 mm below dura; SFO: 1.3 mm caudal to bregma,
midline, 4.5 mm below dura [differences between these levels and
those depicted in the representative atlas sections in Figures 1–3
are accounted for by the age difference of our rats (∼250 g) and
those (∼290 g) used to construct the reference atlas]. Injections
to all structures were made using single-barreled micropipettes
(1–5 µl pre-calibrated microcapillary tube, Sigma Aldrich,
United Kingdom) using a binocular surgical microscope.
Microinjection of Ang II (100 pmol 100 nl−1; Tocris Bioscience,
United Kingdom) was used to functionally confirm the position
of the pipette within the CVOs by recording a rise in arterial
pressure (Reaux et al., 2001). The injection volume was 100
nl. Subsequent microinjections of [Pyr1]apelin-13 or vehicle
were made at the same stereotaxic coordinates that elicited the
largest Ang II pressor response (∼8–10 mmHg). The effective
dose of [Pyr1]apelin-13 was determined by a dose response
course (67, 200, 600, and 1800 pmol 100 nl−1; n = 6/group)
measuring [Pyr1]apelin-13-induced cardiovascular effects in
the CVOs and was found to be maximally effective at 200
pmol 100 nl−1 in each CVO. A subset of animals received a
microinjection of Indian ink (100 nl, 1:10 dilution) at the end
of the experiment to confirm the location of the stereotaxic
coordinates used. After the final microinjection, rats were
deeply anesthetized with sodium pentobarbital and euthanized
by decapitation.
Chronic Arterial Blood Pressure
Measurement
Chronic Femoral Vein Cannulation
Intravenous (i.v.) cannulas were constructed and implanted
as described previously (Griffiths et al., 2018) to allow i.v.
administration of pharmacological compounds. Briefly, adult
WKY (n = 34) and SHR (n = 34) rats were anesthetized with
isoflurane (4% for induction and 2% for maintenance in O2) and
provided with analgesia (Vetergesic; 0.8 mg kg−1). Cannulas were
implanted in the left femoral vein, tunneled subcutaneously, and
externalized between the scapulae. Following surgery, rats were
housed singly in a soundproofed room. Cannulae were flushed
with 0.5 ml heparinized saline (50 IU ml−1) daily for 1 week
following surgery and then every other day for the remainder
of the experiment.
Telemeter Implantation
A radiotelemetry system (TRM54P, Kaha Sciences, Auckland,
New Zealand) was adopted to make chronic, continuous
measurements of arterial pressure as we have reported previously
(McBryde et al., 2013; Griffiths et al., 2018). Adult WKY (n = 34)
and SHR (n = 34) rats underwent telemetry surgery 3 days
following i.v. cannulation. Animals were allowed 6 days recovery
following telemeter implantation before continuous recording of
BP for 5 days before (baseline), and 18 days after (experimental),
virus injection surgeries.
Gene Transfer
Transfer of Viral Vectors Into the CVOs
The aplnr-specific (LV-APJ-shRNA) and non-targeting
scrambled (LV-scr-shRNA) short hairpin RNAs (shRNAs),
incorporating green fluorescent protein (GFP), were expressed in
the lentiviral transfer vector pRRL.SIN.CPPT.CMV.GFP.WPRE
(modified from Addgene plasmid 12252). Lentiviral particles
(LV) were produced using packaging plasmids pMDLg/pRRE,
pRSV-Rev and PMD2.G (Addgene) to a titer of LV-APJ-shRNA,
1.12 × 1010 pfu ml−1 and LV-scr-shRNA, 4.3 × 109 pfu ml−1
as described previously (Griffiths et al., 2018). The effective time
point after virus transfection into the CVOs was determined by
a time course (18 and 25 days; n = 8/group) measuring loss of
[Pyr1]apelin-13-induced cardiovascular effects in the CVOs and
was found to be maximally effective at 18 days.
Intraparenchymal Injection of Lentivirus
Eleven days post telemeter implantation and after 5 days of
baseline recording, WKY and SHR rats (n = 34/group) were
randomly assigned to either the LV-APJ-shRNA or control LV-
scr-shRNA lentiviral particles group. Animals were anesthetized
with an intramuscular injection of ketamine (60 mg kg−1) and
medetomidine (250 µg kg−1), analgesia administered (Vetergesic
0.8 mg kg−1), and microinjected either individually in one of the
OVLT (n = 4/group), SFO (n = 6/group) or AP (n = 4/group), or
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FIGURE 1 | Central apelin microinjection into the OVLT decreases arterial blood pressure. (A) Schematic illustrating the localization of injection sites (symbols
indicate injection sites) in the OVLT, representative of sections (level relative to bregma indicated) from each animal group, determined by examination of the
deposition of dye in the brain stem of animals. In inset: aca, anterior commissure, anterior part; AcbC, accumbens nucleus, core; HDB, nucleus of the horizontal limb
of the diagonal band; LPO, lateral preoptic area; SIB, substantia innominata, basal part; STMA, bed nucleus of the stria terminalis, medial division, anterior part;
VOLT, vascular organ of the lamina terminalis (or OVLT); VDB, nucleus of the vertical limb of the diagonal band; VP, ventral pallidum (adapted from Paxinos and
Watson, 2005; Figure 28). (B) Representative raw traces, binned over 1 s, showing the BP response in single animals following microinjection of [Pyr1]apelin-13 (200
pmol 100 nl−1), angiotensin II (Ang II) (100 pmol 100 nl−1), and saline to the OVLT. The dotted line indicates the microinjection of compound. (C) Change in MABP
following microinjection of saline, Ang II (100 pmol 100 nl−1) and [Pyr1]apelin-13 (200 pmol 100 nl−1) to the OVLT of Wistar rats (n = 6). Data is mean ± SEM with
individual responses. Data analyzed with 1-way ANOVA followed by Tukey’s Multiple Comparison test. ***P < 0.001.
in the three CVOs simultaneously (n = 3/group), with either LV-
APJ-shRNA or LV-scr-shRNA (titre > 109 transforming units/ml;
1 µl). The micropipette was advanced to the correct depth for
the structure of interest (using the brain coordinates outlined
above) and allowed to rest for 5 min prior to viral vector (1
µl) delivery over a period of 10 min. The pipette was then left
in situ for a further 5 min to minimize back-tracking of the
virus. Anesthesia was reversed by a subcutaneous injection of
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FIGURE 2 | Central apelin microinjection into the SFO decreases arterial blood pressure. (A) Schematic illustrating the localization of injection sites (symbols indicate
injection sites) in the SFO, representative of sections (level relative to bregma indicated) from each animal group, determined by examination of the deposition of dye
in the brain stem of animals. In inset: D3V, dorsal 3rd ventricle; df, dorsal fornix; Sfi, septofimbrial nucleus; SFO, subfornical organ; TS, triangular septal nucleus; vhc,
ventral hippocampal commissure (adapted from Paxinos and Watson, 2005; Figure 42). (B) Representative raw traces, binned over 1 s, showing the BP response in
single animals following microinjection of [Pyr1]apelin-13 (200 pmol 100 nl−1), angiotensin II (Ang II) (100 pmol 100 nl−1), and saline to the SFO. The dotted line
indicates the microinjection of compound. (C) Change in MABP following microinjection of saline, Ang II (100 pmol 100 nl−1) and [Pyr1]apelin-13 (200 pmol 100
nl−1) to the SFO of Wistar rats (n = 6). Data is mean ± SEM with individual responses. Data analyzed with 1-way ANOVA followed by Tukey’s Multiple Comparison
test. ***P < 0.001.
antisedan (1 mg kg−1). BP recording continued for 18 days (see
data acquisition below).
Terminal Experiment
Chronic Aplnr CVO Knockdown and Cardiovascular
Responses to i.v. Administered Apelin
Eighteen days post virus injection(s), rats were anesthetized with
sodium pentobarbital (50 mg kg−1 i.p.) and cardiovascular
parameters monitored using the implanted telemeter.
[Pyr1]apelin-13 (2 nmol/kg; 300 µl, i.v) and vehicle (saline,
300 µ l, i.v.) was administered to assess any changes in apelin-
induced pressor responses. Following injection, BP was allowed
to recover for 30 min.
Chronic Aplnr CVO Knockdown and Cardiovascular
Responses to Central Microinjection of Apelin
To confirm that chronic knock-down of aplnr blocked mean
arterial blood pressure (MABP) responses, a direct “challenge”
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FIGURE 3 | Central apelin microinjection into the AP decreases arterial blood pressure. (A) Schematic illustrating the localization of injection sites (symbols indicate
injection sites) in the AP, representative of sections (level relative to bregma indicated) from each animal group, determined by examination of the deposition of dye in
the brain stem of animals. In inset: 10 N, dorsal motor nucleus of vagus; AP, area postrema; CC, central canal; CeCV, central cervical nucleus of the spinal cord; Gr,
gracile nucleus; SolC, nucleus of the solitary tract, commissural part; SolDL, solitary nucleus, dorsolateral part; SolIM, nucleus of the solitary tract, intermediate part;
SolM, nucleus of the solitary tract, medial part; SubP, subpostrema area (adapted from Paxinos and Watson, 2005; Figure 150). (B) Representative raw traces,
binned over 1 s, showing the BP response in single animals following microinjection of [Pyr1]apelin-13 (200 pmol 100 nl−1), angiotensin II (Ang II) (100 pmol 100
nl−1), and saline to the AP. The dotted line indicates the microinjection of compound. (C) Change in MABP following microinjection of saline, angiotensin II (Ang II
100 pmol, 100 nl−1) and [Pyr1]apelin-13 (200 pmol 100 nl−1) to the AP of Wistar rats (n = 6). Data is mean ± SEM with individual responses. Data analyzed with
1-way ANOVA followed by Tukey’s Multiple Comparison test. ***P < 0.001.
microinjection of [Pyr1]apelin-13 (200 pmol 100 nl−1) to the
OVLT, SFO, and/or AP, similar to that described previously
for the RVLM (Griffiths et al., 2018), was carried out. BP was
monitored via the implanted telemeter. CVO injections followed
the same protocol described above. Rats were then euthanized
using a guillotine. Brains were immediately frozen on powdered
dry ice and stored at −80◦C to preserve RNA integrity. The
level of aplnr knockdown was confirmed by quantitative PCR
(qPCR) (see below).
RNA Extraction and cDNA Synthesis
Fresh, frozen sections (40 µm) were cut on a cryostat (CM3050
S, Leica Microsystems) and collected on the freezing plate.
Every fifth section was stained with 0.1% toluidine blue to aid
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identification of the CVOs and samples were then collected
using a 1 mm diameter micropunch (Fine Scientific Tools) and
placed into separate 1.5 ml RNAse/DNAse-free tubes (Appleton
Woods, United Kingdom) on dry ice and stored at −80◦C, before
RNA extraction. The protocols for RNA extraction and cDNA
synthesis from brain punches have been described previously
(Griffiths et al., 2018).
Real Time qPCR Analysis
Primers used and the protocol followed are as described (Griffiths
et al., 2018). qRT-PCR was carried out in duplicate using
SYBR green (Thermo Fisher Scientific, United Kingdom) on an
ABI StepOnePlus Sequence Detection System (ABI, Warrington,
United Kingdom). All qRT-PCR reactions were followed by
dissociation curve analysis. For relative quantification of gene
expression the 2−11CT method was employed (Livak and
Schmittgen, 2001). The internal control genes used were
the housekeeping genes ribosomal protein L19 (Rpl19) and
glyceraldehyde 3-phosphate dehydrogenase (Gapdh).
Data Analysis
BP waveforms were captured using a CED 1401 data capture
system and Spike 2.7 software (CED, United Kingdom) sampled
at 2 kHz. BP waveforms were processed offline using the HRBP
(version 8) script for Spike 2 in order to extract systolic (SABP),
diastolic (DABP) and MABP, pulse interval (PI), respiratory rate
(RR), and heart rate (HR) waveforms. For acute experiments
on exogenous [Pyr1]apelin-13 microinjection into Wistar rat
CVOs using pressure transducers, representative MAPB readings
are shown and data is presented as change in physiological
variable by subtraction of the post-microinjection response
from the pre-microinjection baseline for each compound. BP
data are presented as mean ± SEM and tested for statistical
significance using a repeated measures 1-way ANOVA followed
by Tukey’s Multiple Comparison test using Graphpad Prism
8.0 software for Mac (Graphpad Software Inc., United States).
Statistical significance for differences between groups was defined
as P < 0.05.
For chronic experiments on aplnr CVO knockdown, baseline
values of physiological variables were recorded and averaged over
5 days before virus injection surgery. In these studies, raw BP
waveforms were recorded for the first 10 min of each hour and BP,
HR, and RR data was recorded continuously online. Data were
then recorded for a subsequent 18 days following virus injection.
BP, HR and RR data were extracted offline following acute
administration of [Pyr1]apelin-13 or Ang II. Spectral analysis
of systolic BP was performed using HRV1 script for Spike 2
to calculate power in the very low frequency (VLF): 0–0.3 Hz;
LF: 0.3–0.8 Hz and high frequency (HF): 0.8–3.3 Hz frequency
bands (Parati et al., 1995; Japundžić-Žigon, 1998). The following
settings were used to compute the power spectra: time constant
for DC removal: ± 3 s; frequency range of spectra: 0–5.12 Hz;
epoch duration: 25 s; FFT size: 128; window type: Hanning.
While it has been established that LF-SBPV can be used as an
indirect measure of vasomotor sympathetic tone (Waki et al.,
2006; Lozić et al., 2014) there is still an ongoing debate regarding
this use of LV-SBPV as a marker for estimating sympathetic
activation. Therefore, to confirm that any changes in spectral
analysis data between experimental groups was associated with
change in sympathetic nervous activity, rats additionally were
injected with hexamethonium (i.v.; 10 mg kg−1) 16 days after
virus injection to directly assess the relative level of tone as
indicated by the extent of the fall in arterial pressure. The
change in BP following hexamethonium injection was calculated
by subtracting MABP over the 10 s period following injection
from a 10 s baseline period. Statistical analysis was carried out
using Graphpad Prism 8.0 software (Graphpad Software Inc.,
United States). Statistical significance for differences between
groups was defined as P < 0.05. Unless stated differently,
statistical differences between two experimental groups were
evaluated using independent-sample unpaired Student’s t-tests.
Experimenters were not blinded to the conditions being analyzed.
RESULTS
Central Apelin Microinjection Into the
CVOs Decreases Arterial Blood Pressure
Schematics illustrating the localization of injection sites in the
OVLT, SFO, and AP in coronal sections are shown in Figures 1A,
2A, 3A, respectively. Representative raw traces from single
animals showing the BP response following microinjection of
[Pyr1]apelin-13, Ang II, and saline to the OVLT, SFO, and AP are
shown in Figures 1B, 2B, 3B, respectively. Microinjection of Ang
II (100 pmol) into the OVLT, SFO, or AP, significantly increased
MABP in the OVLT (Figure 1C), SFO (Figure 2C), and AP
(Figure 3C) of Wistar rats, compared to saline-injected controls.
Microinjection of [Pyr1]apelin-13 (200 pmol) into the OVLT,
SFO, or AP decreased MABP (Figures 1C, 2C, 3C, respectively)
compared to saline-injected controls.
Peripheral Apelin Injection Decreases
Arterial Blood Pressure in SHR and WKY
Rats
Baseline physiological variables in awake normotensive WKY
rats and hypertensive SHRs are summarized in Table 1.
Baseline MAPB was 103 ± 3 vs. 138 ± 3 mmHg in WKY
TABLE 1 | Baseline physiological parameters measured prior to virus injection in










DABP (mmHg) 83 ± 3 87 ± 5 106 ± 4 117 ± 3
SABP (mmHg) 127 ± 3 127 ± 5 169 ± 4 181 ± 3
MABP (mmHg) 103 ± 3 104 ± 5 138 ± 3 147 ± 2
PP (mmHg) 44 ± 1 44 ± 1 64 ± 1 64 ± 1
RR (breaths/min) 93 ± 1 93 ± 1 87 ± 1 88 ± 1
HR (bpm) 312 ± 5 314 ± 7 306 ± 3 308 ± 2
Weight (g) 245 ± 3 243 ± 3 268 ± 3 263 ± 2
Data is mean ± SEM, n = 17/group.
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and SHR, respectively. Representative raw traces from single
animals showing the change in MABP following i.v. injection of
[Pyr1]apelin-13 in WKY rats and SHRs are shown in Figure 4A.
Peripheral injection of [Pyr1]apelin-13 (2 nmol/kg; i.v. by femoral
vein) in both WKY rats and SHRs decreased MABP and LF-
SBPV (Figures 4B,C, respectively) compared to saline-injected
controls. The decrease in MABP in response to i.v. [Pyr1]apelin-
13 was significantly greater in SHR than in WKY rats (Figure 4B).
Aplnr Expression Is Up-Regulated in
OVLT, SFO, and AP of SHR
To examine aplnr expression in the CVOs from normotensive
and hypertensive rats, expression levels in micropunches of
CVOs from WKY rats and SHRs were quantified using
qPCR. Aplnr transcript levels were higher in OVLT, SFO,
and AP in SHRs in comparison with WKY control rats
(Figures 4D–F, respectively).
LV-APJ-shRNA-Injection in Individual
CVOs in WKY and SHRs Decreases Aplnr
Expression and Silences Cardiovascular
Responses to Microinjection of
[Pyr1]apelin-13
Lentiviral vector-mediated gene delivery was used to
knockdown aplnr expression in each of the OVLT, SFO,
and AP individually in WKY rats and in SHRs. qPCR analysis
of micropunches from the CVOs of animals microinjected
FIGURE 4 | Peripheral [Pyr1]apelin-13 injection decreases arterial blood pressure and SBPV in SHR and WKY rats and aplnr expression is up-regulated in the CVOs.
(A) Representative raw traces showing the BP response in single animals following peripheral i.v. injection (vertical dotted line) of [Pyr1]apelin-13 (2 mol/kg) and saline
to WKY and SHR rats. Change in (B) MABP and (C) LF-SBPV following i.v. injection of saline and [Pyr1]apelin-13 (2 mol/kg) to WKY (light gray bar, circles) and SHR
(dark gray bar, triangles) rats. Data is mean ± SEM with individual responses (n = 14/group). In (B) [Pyr1]apelin-13-injected WKY rats vs. [Pyr1]apelin-13-injected
SHRs was analyzed with Student’s unpaired t-test, ####P < 0.0001. All other data in (B,C) was analyzed with Student’s paired t-tests, ****P < 0.0001. Relative
expression of aplnr in (D) OVLT, (E) SFO and (F) AP micropunches from WKY (light gray bar, circles) and SHR (dark gray bar, triangles) rats. Data is mean ± SEM
with individual responses (n = 6/group). Data analyzed with Student’s unpaired t-tests. *P < 0.05, **P < 0.01, ***P < 0.001.
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with LV-APJ-shRNA confirmed successful knockdown of
aplnr expression in the OVLT, SFO, or AP at day 18 post-
virus injection in WKY rats (Figures 5A,E,I, respectively)
and SHRs (Figures 5C,G,K, respectively) compared with
those control animals injected with LV-scr-shRNA. The
effectiveness of the LV-APJ-shRNA injection was additionally
verified by measuring the cardiovascular responses of rats
to a challenge microinjection of [Pyr1]apelin-13 individually
into each of the OVLT, SFO or AP of anesthetized WKY and
SHRs at day 18 post-virus injection. For each of the OVLT,
FIGURE 5 | LV-APJ-shRNA-injection in individual CVOs in WKY and SHRs decreases aplnr expression and silences cardiovascular responses to microinjection of
[Pyr1]apelin-13. Relative aplnr expression in micropunched tissue (A,C,E,G,I,K) and change in MABP following microinjection of [Pyr1]apelin-13 (200 pmol 100 nl−1)
(B,D,F,H,J,L) 18 days following microinjection of either LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares) to the OVLT of WKY (A,B)
and SHR (C,D) rats (n = 4/group), to the SFO of WKY (E,F) and SHR (G,H) rats (n = 6/group), and to the AP of WKY (I,J) and SHR (K,L) rats (n = 4/group). Data is
mean ± SEM with individual responses. Data analyzed with Student’s unpaired t-tests. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Frontiers in Physiology | www.frontiersin.org 9 August 2021 | Volume 12 | Article 711041
fphys-12-711041 July 29, 2021 Time: 16:27 # 10
Griffiths et al. Aplnr Knockdown in Sensory CVOs
SFO, and AP, microinjection of [Pyr1]apelin-13 decreased
MABP in LV-scr-shRNA-injected-WKY rats (Figures 5B,F,J,
respectively) and -SHRs (Figures 5D,H,L, respectively).
Knockdown of aplnr in the individual CVOs by LV-APJ-
shRNA-injection prevented this decrease in MABP in response
to microinjection of [Pyr1]apelin-13 into the OVLT, SFO,
or AP of WKY rats (Figures 5B,F,J, respectively), or SHRs
(Figures 5D,H,L, respectively).
Individual CVO-Targeted Chronic Aplnr
Knockdown Does Not Block the
Peripheral Depressor Effect of
[Pyr1]apelin-13 in Normotensive or
Hypertensive Rats
At any point during the 18-day monitoring period, no significant
difference was seen in MABP or LF-SBPV between animals
transduced individually in either the OVLT, SFO, or AP with
either LV-APJ-shRNA or LV-scr-shRNA in WKY rats or SHRs
(Table 2). Falls in MABP induced by i.v. hexamethonium
injection were similar between all OVLT, SFO, and AP LV-APJ-
shRNA- or LV-scr-shRNA-injected WKY rats or SHRs (Table 2).
At day 18 post-virus injection, all groups of individual CVO-
targeted WKY and SHRs were injected i.v. with [Pyr1]apelin-13
or saline control and MABP recorded. The decrease in MABP
observed following peripheral administration of [Pyr1]apelin-
13 was maintained despite aplnr knockdown individually in
the OVLT, SFO, or AP of WKY rats or SHRs (Table 2).
Similarly, the decrease in LF-SBPV observed following peripheral
administration of [Pyr1]apelin-13 was maintained despite aplnr
knockdown individually in the OVLT, SFO, or AP of WKY rats
or SHRs (Table 2).
Multiple CVO-Targeted Aplnr
Knockdown Does Not Block the
Peripheral Depressor Effect of
[Pyr1]apelin-13 in Normotensive Rats
To elucidate whether multiple knockdown of aplnr expression
simultaneously in the OVLT, SFO and AP in the same animal
affects the depressor effect of peripherally-injected [Pyr1]apelin-
13, WKY rats were injected with either LV-APJ-shRNA or
LV-scr-shRNA in the three CVOs. qPCR analysis of aplnr
in micropunches from the OVLT, SFO, and AP showed
knockdown of aplnr in WKY rats injected with LV-APJ-shRNA
simultaneously into the three CVOs when compared with LV-
scr-shRNA-injected rats (Figures 6A–C, respectively). A fall in
MABP was seen in LV-scr-shRNA-injected WKY rats following
a challenge microinjection of [Pyr1]apelin-13 separately into the
OVLT, SFO, or AP (Figures 6D–F, respectively). In comparison,
the decrease in MABP did not persist in LV-APJ-shRNA-injected
WKY rats (Figures 6D–F, respectively). These data confirm
knockdown of aplnr by LV-APJ-shRNA-injection in the three
regions.
TABLE 2 | Individual OVLT-, SFO-, or AP-targeted knockdown of aplnr in WKY and SHR rats.
WKY SHR
Targeted CVO LV-scr-shRNA LV-APJ shRNA LV-scr-shRNA LV-APJ shRNA
Time course 1 MABP (mmHg)
OVLT −3.07 ± 2.65 1.68 ± 2.37 14.39 ± 7.54 16.26 ± 5.75
SFO 1.59 ± 1.44 −0.93 ± 1.13 1645 ± 3.01 10.72 ± 1.64
AP 2.28 ± 2.18 0.28 ± 3.33 9.94 ± 1.21 17.45 ± 2.24
Time course 1 LF-SBPV (% total power)
OVLT −3.28 ± 0.88 −2.08 ± 0.60 −3.92 ± 0.70 −2.93 ± 1.92
SFO −2.17 ± 0.95 −1.72 ± 0.53 −2.58 ± 1.51 −4.62 ± 1.58
AP −1.81 ± 0.98 −2.16 ± 1.12 −2.82 ± 1.18 −2.83 ± 0.88
Effect of hexamethonium 1 MABP (mmHg)
OVLT −15.27 ± 1.44 −14.95 ± 1.42 −20.63 ± 1.16 −23.54 ± 1.62
SFO −17.96 ± 0.71 −18.14 ± 2.11 −18.80 ± 4.10 −17.60 ± 1.17
AP −16.27 ± 1.75 −17.95 ± 2.89 −20.63 ± 1.16 −23.54 ± 1.62
Effect of i.v. [Pyr1]apelin-13 injection 1 MABP (mmHg)
OVLT −7.85 ± 0.85 −8.24 ± 0.98 −16.24 ± 2.97 −14.29 ± 3.25
SFO −9.13 ± 1.66 −9.72 ± 2.21 −17.96 ± 0.71 −18.14 ± 2.11
AP −8.32 ± 0.97 −9.46 ± 1.71 −20.74 ± 4.78 −15.54 ± 4.43
Effect of i.v. [Pyr1]apelin-13 injection 1 LF-SBPV (% total power)
OVLT −5.01 ± 0.97 −4.46 ± 1.41 −5.09 ± 1.54 −7.56 ± 0.97
SFO −3.67 ± 1.69 −5.45 ± 1.57 −3.54 ± 0.13 −4.50 ± 1.10
AP −5.89 ± 1.15 −5.40 ± 0.60 −8.74 ± 2.26 −5.61 ± 1.41
Individual OVLT- (n = 4/group), SFO- (n = 6/group), or AP-targeted (n = 4/group) knockdown of aplnr in WKY or SHR rats had no effect on chronic MABP (mm Hg),
chronic LF-SBPV (% total power), hexamethonium-induced falls in MABP (mm Hg), the peripheral depressor effect of [Pyr1]apelin-13 (mm Hg) or the peripheral-induced
decrease in LF-SBPV (% total power). Data is mean ± SEM.
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FIGURE 6 | Simultaneous CVO-targeted aplnr knockdown does not block the peripheral depressor effect of [Pyr1]apelin-13 in WKY rats. Relative aplnr expression in
the OVLT (A), SFO (B), and AP (C), and change in MABP following microinjection of [Pyr1]apelin-13 (200 pmol 100 nl−1) in the OVLT (D), SFO (E), and AP (F),
18 days following microinjection of either LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares) simultaneously to the OVLT, SFO, and AP of
WKY rats (n = 3/group). Data is mean ± SEM with individual responses. Data in (A–F) analyzed with Student’s unpaired t-tests, *P < 0.05, **P < 0.01. (G) Changes
in MABP ranging from 5 days before (−5) to 18 days after microinjection (vertical dotted line) of either LV-scr-shRNA (gray line) or LV-APJ-shRNA (black line)
simultaneously to the OVLT, SFO, and AP of WKY rats (n = 3/group). Inset bar graph shows change in MABP calculated as MABP at day -5 subtracted from MABP
at day 17. (H) Change in LV-SBPV after microinjection of either LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares), calculated as
LF-SBPV at day -5 subtracted from LF-SBPV at day 17 (n = 3/group). (I) Change in MABP following hexamethonium (10 mg kg−1, i.v.) injection at day 16 post
LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares) injection (n = 3/group). (J) Representative raw traces showing changes in MABP in
single animals in response to i.v. [Pyr1]apelin-13 (black symbols, 2 mol/kg) or saline (gray symbols) in WKY rats injected simultaneously in the OVLT, SFO, and AP
with either LV-APJ-shRNA (squares) or LV-scr-shRNA (circles). Change in MAPB (K) and LV-SBPV (L) following peripheral administration of [Pyr1]apelin-13 (2 nmol
kg−1) to WKY rats (n = 3/group) 18 days post-injection in the OVLT, SFO, and AP with either LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar,
squares). Data in panels (G–L) is mean ± SEM with individual responses and analyzed with Student’s unpaired t-tests.
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Body weights did not differ between LV-APJ-shRNA- and
LV-scr-shRNA-transduced WKY groups over the monitoring
period (Table 1). Resting MABP (Figure 6G and insert) and LF-
SBPV (Figure 6H) were unchanged in LV-APJ-shRNA-injected
rats compared to LV-scr-shRNA-injected rats over the 18 day
monitoring period. No change was seen in hexamethonium-
induced falls in MABP between animals injected with LV-APJ-
shRNA- or LV-scr-shRNA in the OVLT, SFO, and AP (Figure 6I).
Representative raw traces of MABP following administration
of i.v. [Pyr1]apelin-13 or saline in single WKY rats with multiple
CVO aplnr knockdowns at day 18 post-virus injection are shown
in Figure 6J. Peripheral i.v injection of [Pyr1]apelin-13 in LV-scr-
shRNA WKY rats decreased MABP (Figure 6K) and LV-SBPV
(Figure 6L). The decrease in both MABP and LV-SBPV persisted
in LV-APJ-shRNA-injected WKY rats despite knockdown of
aplnr in the 3 sites (Figures 6K,L, respectively).
Multiple CVO-Targeted Aplnr
Knockdown Attenuates the Peripheral
Depressor Effect of [Pyr1]apelin-13 in
Hypertensive Rats
At 18-days post shRNA-injection, qPCR evaluation of
micropunched OVLT, SFO, and AP tissues confirmed
knockdown of aplnr (Figures 7A–C, respectively), and
the expected decrease in MABP following microinjection
of [Pyr1]apelin-13 onto the OVLT, SFO, and AP was
prevented (Figures 7D–F, respectively) in multiple CVO-
targeted LV-APJ-shRNA-injected SHRs in comparison to
LV-scr-shRNA-injected SHRs.
No change was observed in MABP (Figure 7G and insert)
and LF-SBPV (Figure 7H) between LV-APJ-shRNA-injected and
LV-scr-shRNA-injected SHRs over the 18 day observation period
after aplnr knockdown in all three CVO structures. Additionally,
no change was seen in hexamethonium-induced falls in MABP
between SHRs injected concurrently with LV-APJ-shRNA- or
LV-scr-shRNA in all three sensory CVOs (Figure 7I).
Representative raw traces showing changes in MABP in
response to i.v. [Pyr1]apelin-13 or saline administration in single
SHRs simultaneously injected in the OVLT, SFO, and AP with
either LV-scr-shRNA or LV-APJ-shRNA are shown (Figure 7J).
Peripheral i.v injection of [Pyr1]apelin-13 in LV-scr-shRNA-
injected SHRs decreased both MABP (Figure 7K) and LV-SBPV
(Figure 7L) at day 18 post-shRNA injection. This decrease in
MABP and LF-SBPV was significantly attenuated (Figures 7K,L,
respectively) in SHRs with multiple CVO-targeted knockdown of
aplnr in the same animal by LV-APJ-shRNA-injection.
DISCUSSION
The mechanisms by which peripheral and central apelin
modulates BP remains a major question. For example, whether
blood-borne apelin acts at the same locus as centrally synthesized
apelin is unknown and indeed the neuronal circuitry expressing
apelin is not fully understood. The present study examines
the role of APJ in the sensory CVOs for regulation of
arterial pressure in SHR and WKY rats. We reveal a number
of novel findings. First, aplnr is up-regulated in the OVLT,
SFO, and AP in SHRs in comparison to WKY rats. Second,
microinjection of [Pyr1]apelin-13, acting via APJ, into any of
the three CVOs decreases MABP and this is greater in the
SHR. Third, knockdown of aplnr in the CVOs, either collectively
or individually, affects neither resting MABP nor an indirect
measure of sympathetic nerve activity. Fourth, aplnr in the three
CVOs collectively modulates the acute cardiovascular responses
to systemic apelin in hypertensive SHRs but not in normotensive
WKY rats. In SHRs, knockdown of aplnr in the three sensory
CVOs collectively, but not in any CVO individually, reduces both
the depressor and SBPV responses to peripheral [Pyr1]apelin-13
administration.
Our data demonstrates that aplnr is expressed in the CVOs,
where the lack of a BBB may facilitate the interaction of
circulating apelin with APJ present in these structures. Aplnr is
up-regulated in the OVLT, SFO, and AP of SHRs in comparison
to WKY rats, consistent with our earlier study showing increased
aplnr expression in the SFO of SHRs (Griffiths et al., 2020) and
with other studies showing an up-regulated aplnr expression
in the PVN and RVLM of SHRs (Zhang et al., 2014; Griffiths
et al., 2018). It is currently unknown whether these changes in
aplnr levels correspond to changes in levels of functional protein,
however, we have shown an augmented depressor response
to microinjection of [Pyr1]apelin-13 in the SHR CVOs in
comparison to WKY rats, that supports raised APJ expression in
the SHR. The factors that drive increased aplnr expression in the
SHR CVOs are not known. The up-regulation in gene expression
may be compensatory and contribute to the effect of apelin
given peripherally. Such compensatory changes [e.g., remodeling
of microvascular and glial cells (Ritz et al., 2009) with possible
alterations of aplnr levels in these cells] may have consequences
for the activity of CVO efferent projections, and may help
modulate BP in the face of hypertension. It is unknown whether
the higher resting sympathetic tone of SHRs (Iriuchijima, 1973;
Judy et al., 1976) contributes to the more pronounced BP
responses to CVO [Pyr1]apelin-13 microinjection observed in
SHRs. Apelinergic gene expression levels are altered in conditions
of hypertension, e.g., myocardium aplnr/apln levels are down-
regulated in experimental heart failure in Dahl salt-sensitive
rats (Iwanaga et al., 2006) and decreased aplnr/apln levels are
seen in the heart and aorta of SHRs compared to normotensive
rats (Zhong et al., 2005), while aplnr/apln levels and apelin/APJ
protein are up-regulated in the PVN of SHR (Zhang et al.,
2014), reflecting a differential peripheral vs. central expression
pattern. Additionally, circulating levels of apelin are decreased
in chronic heart failure (Földes et al., 2003) and in essential
and pulmonary hypertension (Sonmez et al., 2010; Chandra
et al., 2011), and increased in disease states such as aortic
stenosis (Duman et al., 2018), and left ventricular hypertrophy
(Helske et al., 2010). These findings highlight the importance of
understanding the physiological and pathophysiological roles of
central and peripheral apelin in cardiovascular control.
We have previously shown our APJ-specific shRNA viral
vector is successful in in vivo knockdown of central aplnr in
the rat RVLM (Griffiths et al., 2018), with transgene expression
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FIGURE 7 | Simultaneous CVO-targeted aplnr knockdown attenuates the peripheral depressor effect of [Pyr1]apelin-13 in SHRs. Relative aplnr expression in the
OVLT (A), SFO (B), and AP (C), and change in MABP following microinjection of [Pyr1]apelin-13 (200 pmol 100 nl−1) in the OVLT (D), SFO (E), and AP (F), 18 days
following microinjection of either LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares) simultaneously to the OVLT, SFO, and AP of SHRs
(n = 3/group). Data is mean ± SEM with individual responses. Data in panels (A–F) analyzed with Student’s unpaired t-tests, *P < 0.05, **P < 0.01, ***P < 0.001.
(G) Changes in MABP ranging from 5 days before (−5) to 18 days after microinjection (vertical dotted line) of either LV-scr-shRNA (gray line) or LV-APJ-shRNA (black
line) simultaneously to the OVLT, SFO, and AP of SHRs (n = 3/group). Inset bar graph shows change in MABP calculated as MABP at day -5 subtracted from MABP
at day 17. (H) Change in LV-SBPV after microinjection of either LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares), calculated as
LF-SBPV at day -5 subtracted from LF-SBPV at day 17 (n = 3/group). (I) Change in MABP following hexamethonium (10 mg kg−1, i.v.) injection at day 16 post
LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares) injection (n = 3/group). (J) Representative raw traces showing changes in MABP in
single animals in response to i.v. [Pyr1]apelin-13 (black symbols, 2 mol kg−1) or saline (gray symbols) in WKY rats injected simultaneously in the OVLT, SFO, and AP
with either LV-APJ-shRNA- (squares) or LV-scr-shRNA- (circles). Change in MAPB (K) and LV-SBPV (L) following peripheral administration of [Pyr1]apelin-13 (2
nmol/kg) to SHRs (n = 3/group) 18 days post-injection in the OVLT, SFO, and AP with either LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar,
squares). Data in panels (G–L) is mean ± SEM with individual responses and analyzed with Student’s unpaired t-tests, *P < 0.05.
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highly expressed 3 weeks after transfection. Using the same
construct in the present study, we established CVO knockdown
of aplnr in all LV-APJ-shRNA-injected rats. This was confirmed
both by qPCR analysis showing efficient LV-APJ-shRNA-induced
suppression of CVO aplnr expression and also by subsequent
loss of functionality, i.e., loss of APJ CVO depressor response
to apelin in vivo after microinjection of exogenous [Pyr1]apelin-
13 into the CVO, in knockdown animals, demonstrating robust
and reliable reduction of central apelin-mediated cardiovascular
effects in the CVOs by LV-APJ-shRNA.
To investigate the role of aplnr in specific sensory CVOs as
potential sites influencing the effects of central and/or peripheral
apelin on BP regulation, we initially targeted knockdown of aplnr
in individual CVOs in both SHRs and WKY rats. We show
that chronic decreased aplnr expression in any individual CVO
after LV-APJ-shRNA microinjection did not result in a decrease
of MABP, or in sympathoinhibition (measured indirectly using
power spectral analysis and hexamethonium), in normotensive
or hypertensive rats when compared to control LV-scr-shRNA-
injected rats. We also investigated the effect of aplnr knockdown
on the cardiovascular responses to peripherally administered
apelin. This protocol represents physiological conditions, where
injected apelin has access to peripheral APJ and to receptors
present in the CVOs as well, perhaps, in other brain regions—
e.g., at the BBB where APJ is expressed in vascular cells and
astrocytes. Apelin injected i.p. has been shown to increase
hypothalamic (Higuchi et al., 2007) and cerebrospinal fluid
(Sinen and Bülbül, 2021) apelin levels, and to activate c-Fos in
the PVN (Takayama et al., 2008) and CVO (Sinen and Bülbül,
2021), indicating that systemic apelin may be able to cross the
BBB to stimulate central neurons. Based on studies of many
peptides it is unlikely that polar substances such as apelin-13 and
larger apelin fragments would cross the BBB by diffusion but may
enter the brain parenchyma via carrier-mediated and/or receptor
mediated transport (Lee and Jayant, 2019). We demonstrate that
18 days after LV-APJ-shRNA injection into individual CVOs,
the decrease in BP and LF-SBPV observed following peripheral
administration of [Pyr1]apelin-13 was maintained despite aplnr
knockdown in the CVO. Our results suggest that endogenous
APJ activity in individual CVOs has no effect on basal control
of BP and that silencing of aplnr in the OVLT, SFO or AP
individually does not modify the peripheral depressor effect of
[Pyr1]apelin-13.
To clarify the role of aplnr in the CVOs on BP regulation, we
then investigated the BP effects of chronic aplnr knockdown in
three CVOs simultaneously in normotensive and hypertensive
rats. Knockdown of aplnr in three CVOs in the same animals
did not have a significant effect on BP or on indirect measure
of sympathoinhibition monitored over 18 days, indicating
an absence of endogenous apelin-mediated cardiovascular
regulation. In contrast to tonic control of BP, we report acute
effects on both MABP and indirectly measured sympathetic
activity in response to exogenous application of [Pyr1]apelin-13
after simultaneous CVO aplnr knockdown in SHRs. In SHRs,
but not in WKY rats, 18 days after aplnr-specific virus injection,
simultaneous knockdown of aplnr in three CVO structures
caused an immediate attenuation in the depressor effect, and in
LF-SBPV, normally seen in response to peripherally administered
[Pyr1]apelin-13. This suggests that functional APJ is required in
the CVOs for an intact cardiovascular response to peripherally
administered apelin in the hypertensive animal model used in
this study. Thus, it appears that in physiological conditions apelin
does not act in the CVOs to maintain baseline MABP, but
when circulating apelin is increased the integrity of aplnr in the
CVOs may be essential for a conventional BP response to apelin.
An increase of apelin in the circulation, acting upon increased
levels of APJ in the CVOs, may regulate sympathetic outflow
by stimulating descending neural pathways, additionally offering
therapeutic potential for APJ agonism in pathophysiological
conditions. It is important to note that the central circuitry of
APJ-expressing cell bodies and APJ-projecting fibers in either
rodents or humans has not been detailed.
In our study, if APJ in one of the sensory CVOs was solely
responsible for responding to changing levels of circulating
apelin and transmitting this information to autonomic control
centers to regulate BP, then knockdown of aplnr in that discrete
CVO should have resulted in a change in the BP response to
peripherally administered [Pyr1]-apelin-13. The sensory CVOs
are known to operate in a system of functional redundancy
(McKinley et al., 2019) and of reciprocity of communication
with regions of the cerebral cortex that regulate autonomic
function (Menani et al., 2014), and so it is reasonable to
speculate that the loss of functional APJ integrity in one CVO
may be compensated for by the remaining CVOs. By contrast,
SHRs with aplnr CVO knockdown in three CVOs exhibited
a significant deficit in the depressor response to peripheral
[Pyr1]apelin-13, and in an interesting corollary, this deficit
is linked to an attenuation of the spectral activity response
in these rats, an indirect marker of sympathetic tone. Our
findings indicate that multiple CVO aplnr knockdown eliminates
redundancy in these central structures. The sensory CVOs
are not the sole sites of action through which circulating
apelin modulates pathways involved in BP regulation as
silencing of CVO APJ activity did not completely abolish
BP and LV-SBPV responses to [Pyr1]apelin-13 administration;
however, our data indicates that the CVOs play key roles in
this process. To our knowledge the combinatory importance
of the sensory CVOs in the cardiovascular response to
other peripherally administered neuropeptides in vivo has
not been reported.
CVOs such as the SFO, OVLT, and AP exhibit considerable
transcriptomic plasticity in response to experimental
manipulations including thirst (Hindmarch et al., 2008, 2011;
Pool et al., 2020), food deprivation (Hindmarch et al., 2008),
or early life overnutrition (Peterson et al., 2018). Some of this
plasticity is contributed by vascular elements (Morita et al., 2015).
Aplnr is expressed in neurons, glia and vascular endothelial cells
in the brain (Zhang et al., 2016; Griffiths et al., 2020). Gene-
targeted [e.g., single-cell fluorescence in situ hybridization
(FISH)] or global (e.g., single-cell RNAseq) transcriptomic
studies will allow the assessment of the contribution of different
aplnr-expressing CVO cell types in response to elevated BP. Such
studies will also shed light on whether APJ potentially interacts
with other receptors in the CVOs, most notably ones, like the
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angiotensin AT1 receptor, with which it has been shown to
heterodimerize in vitro (Chun et al., 2008).
In summary, we have shown a significant role for APJ in
the CVOs in the regulation of acute cardiovascular responses
to systemic apelin in SHRs. Importantly, this study has
demonstrated the functional significance of APJ in the SFO,
OVLT, and AP collectively as a primary feedback interface
between circulating apelin and critical cardiovascular control
centers that drive SNA activity to regulate BP. Central apelinergic
pathways may be recruited to buffer the peripheral effects
of apelin, working in a coordinated fashion to maintain
BP within normal physiological limits. Understanding the
central circuitry through which systemic apelin affects central
cardiovascular responses will increase our understanding of
the pathogenesis of hypertension and aid in elucidating
the therapeutic potential of the apelinergic pathway in a
hypertensive disease state.
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